Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

Gen­mab $GMAB has opt­ed to ax one of its an­ti­body-drug con­ju­gates af­ter watch­ing it flop in the clin­ic.

The Dan­ish biotech re­port­ed Tues­day that it de­cid­ed to kill their pro­gram for enapotam­ab ve­dotin af­ter the da­ta gath­ered from ex­pan­sion co­horts failed to mea­sure up. Ac­cord­ing to the com­pa­ny:

While enapotam­ab ve­dotin has shown some ev­i­dence of clin­i­cal ac­tiv­i­ty, this was not op­ti­mized by dif­fer­ent dose sched­ules and/or pre­dic­tive bio­mark­ers. Ac­cord­ing­ly, the da­ta from the ex­pan­sion co­horts did not meet Gen­mab’s strin­gent cri­te­ria for proof-of-con­cept.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.